Details of the Drug

General Information of Drug (ID: DMIK367)

Drug Name
Procarbazine
Synonyms
Ibenzmethyzin; Ibenzmethyzine; MBH; MIH; Natulan; Natulanar; PCX; Procarbazin; Procarbazina; Procarbazinum; Procarbazin [German]; Procarbazine Monohydrochloride; CB 400-497; Indicarb (TN); Matulane (TN); Natulan (TN); Procarbazina [INN-Spanish]; Procarbazine (INN); Procarbazine [INN:BAN]; Procarbazinum [INN-Latin];Ro 4-6467; SRI-10847; Ro 4-6467/1; N-4-Isopropylcarbamoylbenzyl-N'-methylhydrazine; N-Isopropyl-4-[(2-methylhydrazino)methyl]benzamide; P-(2-Methylhydrazinomethyl)-N-isopropylbenzamide; N-Isopropyl-p-(2-methylhydrazinomethyl)-benzamide; P-(N'-Methylhydrazinomethyl)-N-isopropylbenzamide; N-(1-Methylethyl)-4-[(2-methylhydrazino)methyl]benzamide; N-Isopropyl-alpha-(2-methylhydrazino)-p-toluamide; N-(1-Methylethyl)-4-((2-methylhydrazino)methyl)benzamide; Benzamide, N-(1-methylethyl)-4-((2-methylhydrazino)methyl)-(9CI); 1-Methyl-2-(p-(isopropylcarbamoyl)benzyl)hydrazine; 2-(p-Isopropylcarbamoylbenzyl)-1-methylhydrazine; 4-((2-Methylhydrazino)methyl)-N-isopropylbenzamide; 4-[(2-methylhydrazinyl)methyl]-N-propan-2-ylbenzamide
Indication
Disease Entry ICD 11 Status REF
Hodgkin lymphoma 2B30 Approved [1]
Therapeutic Class
Anticancer Agents
Affected Organisms
Humans and other mammals
ATC Code
L01XB01: Procarbazine
L01XB: Methylhydrazines
L01X: OTHER ANTINEOPLASTIC AGENTS
L01: ANTINEOPLASTIC AGENTS
L: ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL
#Ro5 Violations (Lipinski): 0 Molecular Weight (mw) 221.3
Logarithm of the Partition Coefficient (xlogp) 0.1
Rotatable Bond Count (rotbonds) 5
Hydrogen Bond Donor Count (hbonddonor) 3
Hydrogen Bond Acceptor Count (hbondacc) 3
ADMET Property
Absorption
The drug is rapidly and completely absorbed []
Half-life
The concentration or amount of drug in body reduced by one-half in 10 minutes [2]
Metabolism
The drug is metabolized via the liver []
MRTD
The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 27.11194 micromolar/kg/day [3]
Chemical Identifiers
Formula
C12H19N3O
IUPAC Name
4-[(2-methylhydrazinyl)methyl]-N-propan-2-ylbenzamide
Canonical SMILES
CC(C)NC(=O)C1=CC=C(C=C1)CNNC
InChI
InChI=1S/C12H19N3O/c1-9(2)15-12(16)11-6-4-10(5-7-11)8-14-13-3/h4-7,9,13-14H,8H2,1-3H3,(H,15,16)
InChIKey
CPTBDICYNRMXFX-UHFFFAOYSA-N
Cross-matching ID
PubChem CID
4915
ChEBI ID
CHEBI:71417
CAS Number
671-16-9
UNII
35S93Y190K
DrugBank ID
DB01168
TTD ID
D08GYO
INTEDE ID
DR1344
ACDINA ID
D00558
Combinatorial Drugs (CBD) Click to Jump to the Detailed CBD Information of This Drug

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Human Deoxyribonucleic acid (hDNA) TTUTN1I NOUNIPROTAC Not Available [4]

Drug-Metabolizing Enzyme (DME)
DME Name DME ID UniProt ID MOA REF
Cytochrome P450 1A1 (CYP1A1) DE6OQ3W CP1A1_HUMAN Substrate [5]
Cytochrome P450 1A2 (CYP1A2) DEJGDUW CP1A2_HUMAN Substrate [5]
Cytochrome P450 1B1 (CYP1B1) DE9QHP6 CP1B1_HUMAN Substrate [6]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Experimental Cancer Drug Sensitivity Information

Cancer Drug Sensitivity Data Curated from 127 Cell Line(s) in Haematopoietic And Lymphoid Tissue Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
JK1 CTRP2 7.563 12.742 3.8611 6.6129
MEC1 CTRP2 7.7669 9.1508 5.5877 0.2638
JM1 CTRP2 8.7177 10.3813 5.5086 0.1456
SU-DHL-6 CTRP2 5.9137 15.8069 1.0538 20.1491
MOLT-16 CTRP2 5.9975 7.1913 5.4314 2.6684
DND-41 CTRP2 6.0883 7.8558 5.175 3.5706
KMS-20 CTRP2 6.1017 7.2032 5.512 2.1295
KMS-26 CTRP2 6.134 7.6791 5.3005 2.9583
Peer CTRP2 6.1814 7.5501 5.4024 2.4454
SUP-T11 CTRP2 6.2201 8.4677 4.9758 4.1638
Ri-1 CTRP2 6.2312 8.0938 5.1709 3.3267
KMS-12-BM CTRP2 6.4177 7.9536 5.3802 2.1486
NCI-H929 CTRP2 6.4866 8.8635 4.9842 3.6722
A4/Fukuda CTRP2 6.5545 8.1432 5.3837 1.9333
WSU-DLCL2 CTRP2 6.6305 7.8454 5.5728 1.0959
JVM-3 CTRP2 6.6614 9.4269 4.8357 4.0063
M-07e CTRP2 6.6905 8.3946 5.3543 1.8648
HPB-ALL CTRP2 6.7048 9.0624 5.044 3.0884
MOLP-8 CTRP2 6.7674 8.6194 5.2981 2.1323
PF-382 CTRP2 6.7954 8.6418 5.3055 1.9201
SU-DHL-10 CTRP2 6.8744 15.9955 1.7425 15.9402
KMS-34 CTRP2 6.9324 9.0715 5.1914 2.1899
EHEB CTRP2 7.0321 9.5921 5.0107 2.7676
Ki-JK CTRP2 7.1912 10.5163 4.6768 3.8751
MOLM-16 CTRP2 7.24 9.5362 5.1656 1.9251
NU-DUL-1 CTRP2 7.2732 10.0328 4.9575 2.6704
MOTN-1 CTRP2 7.2916 8.9429 5.4552 0.8718
PL21 CTRP2 7.3069 8.9224 5.4715 0.8091
MOLT-3 CTRP2 7.3311 8.3138 5.7219 0.1633
KO52 CTRP2 7.3342 8.6589 5.592 0.4471
KHM-1B CTRP2 7.4227 9.535 5.2698 1.3696
DEL CTRP2 7.4459 8.3179 5.7636 0.0762
HEL 92.1.7 CTRP2 7.4464 8.6627 5.6391 0.2819
SIG-M5 CTRP2 7.469 8.3197 5.7712 0.0643
Ci-1 CTRP2 7.4839 8.2619 5.7959 0.0401
ALL-SIL CTRP2 7.4978 9.2243 5.4402 0.7649
CMK CTRP2 7.5037 8.7193 5.6415 0.2545
Mino CTRP2 7.51 8.723 5.6427 0.2498
HT CTRP2 7.5171 8.8063 5.6143 0.3054
HH [Human lymphoma] CTRP2 7.5336 9.5187 5.3352 1.059
A3/Kawakami CTRP2 7.5404 8.7948 5.6282 0.2673
KYO-1 CTRP2 7.5676 9.2368 5.4683 0.6395
Ku812 CTRP2 7.5907 9.4455 5.3943 0.8353
BL-70 CTRP2 7.6023 8.6204 5.7153 0.1052
RCH-ACV CTRP2 7.6191 10.0697 5.1431 1.6204
OCI-AML-5 CTRP2 7.6362 8.4323 5.791 0.0297
HL-60 CTRP2 7.6393 8.8941 5.6313 0.2262
ST486 CTRP2 7.6458 9.0655 5.57 0.3468
KMS-21-BM CTRP2 7.654 9.3732 5.4536 0.627
SR CTRP2 7.6658 10.034 5.1838 1.4406
P31/FUJ CTRP2 7.7039 8.9852 5.6235 0.2194
TALL-1 [Human adult T-ALL] CTRP2 7.7471 12.8611 3.9293 6.0794
THP-1 CTRP2 7.7892 11.2352 4.7186 2.9695
RS4;11 CTRP2 7.8084 9.845 5.3353 0.8582
JeKo-1 CTRP2 7.8349 9.0745 5.6416 0.1541
L-540 CTRP2 7.8493 11.8242 4.4843 3.7818
RL CTRP2 7.8755 9.5331 5.4889 0.4252
CML-T1 CTRP2 7.8891 9.573 5.4794 0.4404
SU-DHL-1 CTRP2 7.8913 8.8824 5.728 0.0497
697 CTRP2 7.8932 9.2702 5.5938 0.213
TF-1 CTRP2 7.906 9.1206 5.6518 0.1248
OCI-M1 CTRP2 7.9118 9.1402 5.6471 0.1297
MHH-CALL-4 CTRP2 7.9163 14.9775 3.0254 9.3885
OCI-Ly3 CTRP2 7.9323 9.2268 5.6242 0.1561
EM-2 CTRP2 7.9453 9.4725 5.5404 0.2912
BV-173 CTRP2 7.9477 10.0684 5.3105 0.8378
Kasumi-2 CTRP2 7.9483 9.4674 5.5435 0.2843
HEL CTRP2 7.965 8.9799 5.7207 0.0477
HuNS1 CTRP2 7.9913 9.604 5.5102 0.333
Karpas-620 CTRP2 7.999 10.0277 5.3504 0.6993
RPMI-8226 CTRP2 8.0051 9.4718 5.5642 0.2297
KMS-11 CTRP2 8.0188 11.8133 4.5919 3.183
SET-2 CTRP2 8.0223 9.2465 5.6503 0.1051
KMS-18 CTRP2 8.0264 11.74 4.6297 3.0359
OCI-AML-3 CTRP2 8.0358 9.2312 5.6603 0.092
MHH-CALL-3 CTRP2 8.0398 11.7703 4.6238 3.0429
SKM-1 CTRP2 8.055 9.1639 5.6899 0.062
P12-Ichikawa CTRP2 8.073 9.2391 5.6707 0.0765
SK-MM-2 CTRP2 8.0791 9.4957 5.5839 0.1791
SUP-B15 CTRP2 8.1119 9.6824 5.5294 0.2569
MV4-11 CTRP2 8.1322 9.8772 5.4658 0.3686
KMS-27 CTRP2 8.1397 9.2335 5.6957 0.0489
ME1 CTRP2 8.142 9.7515 5.516 0.2709
Toledo CTRP2 8.1581 9.9837 5.4365 0.4186
EJM CTRP2 8.1582 9.6528 5.5579 0.1982
RPMI-8402 CTRP2 8.1994 9.6004 5.5917 0.1423
RPMI-6666 CTRP2 8.2116 9.6461 5.5802 0.1545
KM-H2 CTRP2 8.2436 9.5882 5.6119 0.1105
Hs 611.T CTRP2 8.2897 10.3595 5.349 0.5536
Karpas-422 CTRP2 8.2905 9.547 5.6424 0.0743
DB CTRP2 8.303 9.7139 5.5899 0.1251
LP-1 CTRP2 8.3352 9.8244 5.5631 0.1512
Jurkat CTRP2 8.3391 9.7865 5.5778 0.1327
Kasumi-1 CTRP2 8.3438 9.6316 5.6324 0.0765
K-562 CTRP2 8.3556 9.6718 5.6229 0.0833
JURL-MK1 CTRP2 8.3723 9.7165 5.6136 0.0897
LAMA-84 CTRP2 8.3763 10.0193 5.5097 0.2156
NALM-6 CTRP2 8.3776 9.9665 5.5289 0.1875
HD-MY-Z CTRP2 8.3806 9.9637 5.531 0.184
AML-193 CTRP2 8.4001 9.3604 5.7405 0.0132
KE-97 CTRP2 8.434 9.5809 5.6799 0.0356
KE-37 CTRP2 8.4723 9.6058 5.6845 0.0309
MOLP-2 CTRP2 8.4842 13.894 3.9186 5.1647
SUP-T1 CTRP2 8.4868 10.4746 5.3874 0.3922
JJN-3 CTRP2 8.4945 9.8405 5.6142 0.0741
SUP-HD1 CTRP2 8.5165 10.3795 5.434 0.2979
U266B1 CTRP2 8.5417 9.9736 5.5856 0.0931
L-428 CTRP2 8.5428 10.1083 5.54 0.1403
OCI-Ly19 CTRP2 8.5772 10.5718 5.3877 0.3605
MOLM-13 CTRP2 8.6141 10.2131 5.5294 0.1399
NU-DHL-1 CTRP2 8.6469 10.0249 5.6048 0.0654
REC-1 CTRP2 8.6496 10.2907 5.5153 0.1498
OCI-Ly10 CTRP2 8.7193 10.5401 5.4537 0.2146
KCL-22 CTRP2 8.7465 10.3465 5.5308 0.1172
Mono-Mac-1 CTRP2 8.759 11.0471 5.2848 0.4939
Granta-519 CTRP2 8.7598 10.438 5.5041 0.1434
HDLM-2 CTRP2 8.8771 11.1065 5.3105 0.4023
MOLM-6 CTRP2 9.2355 19.4403 1.7831 12
F-36P CTRP2 9.3601 11.1733 5.465 0.098
U-937 CTRP2 9.3814 20.9516 1.1553 13.8731
L-363 CTRP2 9.4739 18.9135 2.1945 10.2479
SU-DHL-8 CTRP2 9.957 22.3918 0.8568 14.0017
AMO1 CTRP2 10.2256 22.5761 0.9498 13.3491
P3HR-1 CTRP2 10.3619 21.1507 1.7149 10.7248
MC116 CTRP2 10.4841 23.4666 0.6977 13.7738
MM1.S CTRP2 11.0723 22.2044 1.6712 10.0023
SU-DHL-4 CTRP2 12.6558 28.9818 -0.4938 14.4082
⏷ Show the Full List of 127 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 23 Cell Line(s) in Oesophagus Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
TE15 CTRP2 8.2772 10.1171 5.4354 0.3748
TE8 CTRP2 8.467 19.2494 1.3359 14.6537
KYSE-150 CTRP2 7.9507 9.2758 5.6137 0.1668
KYSE-180 CTRP2 8.0968 10.1252 5.3559 0.6321
KYSE-450 CTRP2 8.1613 9.4135 5.6425 0.0914
TE-1 CTRP2 8.1728 11.2463 4.9299 1.8405
EC-GI-10 CTRP2 8.2389 10.0519 5.4441 0.3717
OE33 CTRP2 8.2704 10.8956 5.1269 1.1484
KYSE-510 CTRP2 8.2921 9.627 5.6158 0.0989
KYSE-70 CTRP2 8.3405 10.0295 5.4924 0.252
KYSE-30 CTRP2 8.4024 9.6851 5.6346 0.0679
TE-9 CTRP2 8.4119 9.6497 5.6497 0.0557
KYSE-410 CTRP2 8.4967 13.4859 4.1143 4.4161
OE21 CTRP2 8.5946 10.3193 5.4852 0.1991
TE-11 CTRP2 8.72 10.1478 5.5887 0.0699
TE-10 CTRP2 8.8559 10.6763 5.4563 0.1824
KYSE-520 CTRP2 8.8721 10.5908 5.4917 0.1384
TE-14 CTRP2 8.8888 10.4235 5.5543 0.0786
COLO 680N CTRP2 8.9252 10.3014 5.6071 0.0418
TE-6 CTRP2 10.1255 27.5973 -1.5492 20.2547
TE-4 CTRP2 10.6736 28.677 -1.6845 19.8124
KYSE-140 CTRP2 12.3736 33.6319 -2.8974 20.2458
OE19 CTRP2 14.89 32.1856 -0.5972 12.2871
⏷ Show the Full List of 23 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 36 Cell Line(s) in Pancreas Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
N2a-PK1 CTRP2 8.3631 14.4654 3.574 6.6325
QGP-1 CTRP2 7.5708 9.2 5.4846 0.5934
KP-2 CTRP2 7.6088 8.8359 5.6406 0.2193
L3.3 CTRP2 7.633 9.2586 5.4896 0.5445
SNU-213 CTRP2 7.6704 8.8733 5.6511 0.1825
HPAC CTRP2 7.722 9.9305 5.2572 1.156
MIA PaCa-2 CTRP2 7.7403 9.0658 5.6084 0.2347
Panc 03.27 CTRP2 7.8425 10.0927 5.2497 1.1679
PaTu 8988t CTRP2 7.8524 18.3466 1.3274 16.5972
YAPC CTRP2 7.86 9.1084 5.6391 0.1519
KP-4 CTRP2 7.9193 9.5016 5.5191 0.3425
Capan-1 CTRP2 7.9484 9.9796 5.3465 0.739
TCC-Pan2 CTRP2 8.0032 10.41 5.1972 1.1286
SU.86.86 CTRP2 8.041 21.3353 -0.0076 19.481
SNU-410 CTRP2 8.1093 10.369 5.2647 0.8632
SUIT-2 CTRP2 8.1185 9.1753 5.7078 0.0426
Hs 766T CTRP2 8.204 9.6149 5.5883 0.1456
Panc 02.03 CTRP2 8.2176 9.631 5.5877 0.1543
HuP-T3 CTRP2 8.2359 10.1452 5.4079 0.4472
Panc 05.04 CTRP2 8.242 10.2761 5.3606 0.5491
PK-59 CTRP2 8.2805 13.045 4.1856 4.4006
PaTu 8902 CTRP2 8.3011 9.6517 5.6106 0.1029
PSN1 CTRP2 8.3123 10.1955 5.4204 0.4202
HPAF-II CTRP2 8.3885 10.2167 5.4431 0.3218
SW1990 CTRP2 8.4029 10.3032 5.4171 0.3651
BxPC-3 CTRP2 8.4048 10.2609 5.4334 0.3341
HuP-T4 CTRP2 8.5761 10.3641 5.4624 0.2363
Panc 08.13 CTRP2 8.7209 10.3042 5.5362 0.1156
AsPC-1 CTRP2 8.7318 10.5818 5.4437 0.2259
PK-45H CTRP2 8.798 10.4758 5.5048 0.1363
Capan-2 CTRP2 8.8314 10.4466 5.5266 0.1093
PaTu 8988s CTRP2 9.0194 16.4152 3.0791 7.6486
KP-3 CTRP2 9.0794 10.8519 5.4759 0.1235
DAN-G CTRP2 13.8903 40.0396 -4.9422 22.2119
CFPAC-1 CTRP2 14.7402 38.3053 -3.542 18.8424
Panc 04.03 CTRP2 15.18 31.5425 -0.1363 10.8564
⏷ Show the Full List of 36 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 49 Cell Line(s) in Skin Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
SH4 CTRP2 8.1051 12.6861 4.2434 4.3909
SK-MEL-28 CTRP2 6.9626 7.81 5.7596 0.2273
SK-MEL-31 CTRP2 7.1342 8.6635 5.4928 0.8797
Malme-3M CTRP2 7.1639 10.3971 4.7155 3.7586
A2058 CTRP2 7.2201 8.5547 5.581 0.5861
Hs 839.T CTRP2 7.2389 8.2004 5.7271 0.1842
UACC-62 CTRP2 7.3531 8.5096 5.6581 0.2802
A101D CTRP2 7.3652 9.5789 5.2186 1.7208
SK-MEL-2 CTRP2 7.3684 8.5 5.6681 0.2716
SK-MEL-5 CTRP2 7.4261 9.896 5.1118 1.9218
Hs 944.T CTRP2 7.4621 10.245 4.9749 2.3843
IGR-39 CTRP2 7.5441 8.6635 5.678 0.1871
SK-MEL-30 CTRP2 7.5492 9.0973 5.5156 0.5242
HMCB CTRP2 7.5881 8.5867 5.7218 0.1071
SK-MEL-3 CTRP2 7.6327 9.0532 5.5692 0.3542
Hs 294T CTRP2 7.6621 9.1795 5.5333 0.4534
MDA-MB-435S CTRP2 7.7022 9.3096 5.5004 0.4809
RVH-421 CTRP2 7.7047 9.6987 5.3453 0.8999
Hs 936.T CTRP2 7.7595 9.0489 5.6221 0.2048
WT2-iPS CTRP2 7.7982 8.8245 5.7152 0.0773
CJM [Human melanoma] CTRP2 7.8055 8.9668 5.6687 0.1236
K029AX CTRP2 7.8159 9.341 5.5367 0.3469
WM266-4 CTRP2 7.8305 9.0534 5.6475 0.1468
IGR-1 CTRP2 7.8809 9.4928 5.5065 0.3843
WM793 CTRP2 7.8933 10.0216 5.3037 0.8921
UACC-257 CTRP2 7.9038 9.0095 5.6893 0.0823
SK-MEL-1 CTRP2 7.9068 9.1515 5.6413 0.1384
COLO 829 CTRP2 7.9607 10.0803 5.3117 0.8262
Mel Ho CTRP2 7.9708 9.6498 5.4847 0.3935
Hs 895.T CTRP2 7.9877 9.2933 5.6213 0.1476
WM115 CTRP2 8.0517 9.2434 5.6618 0.0881
WM1799 CTRP2 8.053 9.2812 5.6493 0.101
LOX-IMVI CTRP2 8.0934 9.3864 5.6275 0.1187
MeWo CTRP2 8.0969 11.4511 4.7992 2.3557
COLO 741 CTRP2 8.1361 10.2501 5.3243 0.6903
WM88 CTRP2 8.1366 9.437 5.6256 0.1133
Hs 852.T CTRP2 8.1505 10.3069 5.3083 0.7233
Hs 940.T CTRP2 8.1658 9.8064 5.5054 0.2821
COLO 792 CTRP2 8.2196 9.9809 5.4626 0.3682
RPMI-7951 CTRP2 8.2391 9.8829 5.5062 0.2583
IPC-298 CTRP2 8.2391 9.542 5.6261 0.0964
COLO 800 CTRP2 8.2764 9.7361 5.5725 0.1512
SK-MEL-24 CTRP2 8.3023 9.9366 5.5112 0.2325
G-361 CTRP2 8.3394 9.9731 5.5122 0.2211
A-375 CTRP2 8.4014 9.8017 5.5948 0.1039
HT-144 CTRP2 8.5492 10.2524 5.4919 0.2149
WM983B CTRP2 8.5894 11.0964 5.1938 0.7758
Mel JuSo CTRP2 8.6185 13.2597 4.289 3.6415
IGR-37 CTRP2 12.8414 27.4765 0.3238 12.0098
⏷ Show the Full List of 49 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 1 Cell Line(s) in Ascites Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
COLO 684 CTRP2 8.6976 10.5483 5.4427 0.2529
Cancer Drug Sensitivity Data Curated from 12 Cell Line(s) in Autonomic Ganglia Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
IMR-32 CTRP2 7.3062 8.4147 5.6744 0.2649
SK-N-FI CTRP2 7.5592 9.2186 5.4717 0.6352
SK-N-BE(2) CTRP2 7.5897 9.6634 5.3027 1.1174
Kelly CTRP2 7.5944 9.3733 5.4256 0.7417
SK-N-DZ CTRP2 7.606 8.8355 5.6396 0.222
NH-6 CTRP2 7.9692 9.3302 5.6014 0.1805
CHP-126 CTRP2 8.1264 9.6063 5.5624 0.1994
NB1 CTRP2 8.1651 9.7009 5.5433 0.2189
KP-N-YN CTRP2 8.1889 9.7661 5.529 0.2352
SK-N-AS CTRP2 8.2466 9.5353 5.631 0.0904
SK-N-SH CTRP2 8.3906 9.9932 5.5243 0.2052
CHP-212 CTRP2 8.5604 10.0743 5.5579 0.1176
⏷ Show the Full List of 12 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 7 Cell Line(s) in Biliary Tract Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
HuH-28 CTRP2 7.3202 9.0783 5.4124 0.9854
SNU-478 CTRP2 7.5378 9.1139 5.5038 0.5614
SNU-308 CTRP2 7.976 9.4816 5.5493 0.2646
SNU-869 CTRP2 8.2234 9.6582 5.5802 0.152
HuCC-T1 CTRP2 8.3657 9.981 5.5194 0.2039
SNU-1196 CTRP2 8.5317 9.9273 5.5978 0.0835
SNU-1079 CTRP2 8.5739 10.6196 5.3688 0.3969
⏷ Show the Full List of 7 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 13 Cell Line(s) in Bone Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
TC71 CTRP2 6.696 8.961 5.087 2.927
Hs 822.T CTRP2 7.1688 8.0175 5.7663 0.1363
SK-N-MC CTRP2 7.3895 8.3382 5.7356 0.1249
SW1353 CTRP2 7.6054 10.0509 5.1438 1.6307
A-673 CTRP2 7.6652 8.8494 5.6576 0.1733
CAL-78 CTRP2 7.8618 9.5572 5.4738 0.4658
G-292 clone A141B1 CTRP2 7.9347 9.6453 5.4712 0.4383
MG-63 CTRP2 8.0036 9.2976 5.6257 0.1384
U2OS CTRP2 8.0704 10.9528 5.0021 1.6908
HOS CTRP2 8.2368 9.5413 5.6255 0.1045
SK-ES-1 CTRP2 8.3688 9.9386 5.5355 0.1804
MHH-ES-1 CTRP2 8.5551 10.1872 5.517 0.1657
SJSA-1 CTRP2 9.8063 23.3617 0.2851 15.9241
⏷ Show the Full List of 13 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 65 Cell Line(s) in Breast Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
HDQ-P1 CTRP2 6.6515 9.0778 4.9991 3.3514
KPL-1 CTRP2 6.882 7.6196 5.7981 0.1773
DU4475 CTRP2 7.7131 8.9536 5.6386 0.1908
EFM-192A CTRP2 7.7208 9.9173 5.2622 1.1413
ZR-75-1 CTRP2 7.7408 9.3023 5.5199 0.4162
CAL-51 CTRP2 7.7512 9.9426 5.2669 1.1032
JIMT-1 CTRP2 7.755 11.1546 4.735 2.9473
HCC1428 CTRP2 7.7658 9.134 5.5935 0.2535
Hs 578Bst CTRP2 7.8005 9.2777 5.5541 0.3172
CAL-120 CTRP2 7.8072 9.0017 5.657 0.1388
MDA-MB-231 CTRP2 7.8351 10.1966 5.2024 1.2395
BT-474 CTRP2 7.9133 9.326 5.5814 0.2279
CAMA-1 CTRP2 7.9617 9.4817 5.5436 0.2797
UACC-812 CTRP2 7.9923 9.8879 5.4024 0.5717
HCC1143 CTRP2 8.0107 14.5592 3.2933 8.2078
Hs 578T CTRP2 8.0187 10.05 5.3505 0.6879
HCC1806 CTRP2 8.0606 10.1482 5.3305 0.7162
HCC1395 CTRP2 8.0869 9.9445 5.4214 0.4817
HCC1937 CTRP2 8.1735 10.2001 5.3603 0.5824
MCF-7 CTRP2 8.1775 17.2068 2.1256 12.3638
HCC1500 CTRP2 8.2139 9.7985 5.5269 0.2316
HCC1419 CTRP2 8.2409 9.7391 5.5583 0.1777
SK-BR-3 CTRP2 8.2926 10.0363 5.4713 0.3023
ZR-75-30 CTRP2 8.3667 10.069 5.4883 0.2514
BT-20 CTRP2 8.4243 9.9415 5.5548 0.1443
CAL-85-1 CTRP2 8.4255 10.1983 5.4643 0.2942
MDA-MB-361 CTRP2 8.4844 10.185 5.4916 0.2158
MDA-MB-157 CTRP2 8.5912 10.1866 5.5303 0.1428
T-47D CTRP2 8.6458 10.4737 5.4497 0.2378
MDA-MB-468 CTRP2 8.6651 10.2255 5.5433 0.1167
HCC1954 CTRP2 8.6795 10.3318 5.5119 0.1484
HMC-1-8 CTRP2 12.9843 23.9651 1.9931 7.0042
BT 239 CTRP2 5.9369 7.739 5.1059 4.1572
BT 444 CTRP2 6.7105 9.3548 4.9061 3.6417
BT 498 CTRP2 7.0506 20.9544 -0.5896 22.7748
BT 286 CTRP2 7.3249 11.508 4.292 5.2279
BT 422 CTRP2 7.3519 8.6542 5.6018 0.4125
BT 216 CTRP2 7.3822 10.0288 5.0259 2.2844
BT 320 CTRP2 7.4018 8.4295 5.7075 0.1665
BT 416 CTRP2 7.4354 11.3149 4.4588 4.4086
BT 179 CTRP2 7.4477 8.5937 5.6654 0.2282
BT 340 CTRP2 7.4661 10.179 5.0073 2.2599
BT 172 CTRP2 7.5534 9.1967 5.4778 0.6221
BT 271 CTRP2 7.5776 9.0735 5.5376 0.4536
BT 359 CTRP2 7.5812 9.5102 5.3627 0.9367
BT164 CTRP2 7.6254 8.9822 5.593 0.3062
BT 112 CTRP2 7.6982 8.779 5.695 0.1117
BT 440 CTRP2 7.7418 10.4218 5.056 1.8046
BT 328 CTRP2 7.7959 8.931 5.6777 0.114
BT 131 CTRP2 7.818 9.4475 5.4972 0.4325
BT 232 CTRP2 7.8711 9.5964 5.4627 0.4873
BT 145 CTRP2 7.9009 9.2446 5.606 0.1912
BT 428 CTRP2 7.9323 9.3104 5.5944 0.201
BT 228 CTRP2 7.9451 9.298 5.6037 0.1831
BT 333 CTRP2 8.0003 9.5302 5.5411 0.2714
BT 159 CTRP2 8.0101 9.0797 5.7027 0.0567
BT 504 CTRP2 8.0213 10.497 5.1699 1.1977
BT147 CTRP2 8.1065 9.746 5.5041 0.3039
BT 139 CTRP2 8.1208 9.3067 5.6645 0.0759
BT 224 CTRP2 8.1216 9.5027 5.5973 0.1509
BT 245 CTRP2 8.3027 9.9486 5.507 0.239
BT 482 CTRP2 8.4375 9.5475 5.692 0.0294
BT 231 CTRP2 8.4918 10.2213 5.4814 0.229
BT 248 CTRP2 8.6512 10.1199 5.5743 0.0893
BT 330 CTRP2 12.6095 25.588 1.0504 10.1878
⏷ Show the Full List of 65 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 1 Cell Line(s) in Tongue Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
YD-38 CTRP2 7.7948 8.832 5.7114 0.0762
Cancer Drug Sensitivity Data Curated from 43 Cell Line(s) in Central Nervous System Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
CCF-STTG1 CTRP2 7.1641 8.5376 5.5611 0.6422
KNS-42 CTRP2 7.3168 9.1151 5.3949 1.045
CAS-1 CTRP2 7.32 20.6007 -0.1999 21.2529
DK-MG CTRP2 7.4335 8.7105 5.6155 0.3394
SNU-1105 CTRP2 7.4888 9.2852 5.4106 0.8594
LN-18 CTRP2 7.5998 8.5545 5.7372 0.0796
SNU-626 CTRP2 7.666 8.7129 5.7063 0.1038
Hs 683 CTRP2 7.8112 9.2973 5.5512 0.3191
U-87MG ATCC CTRP2 7.8136 9.3247 5.5419 0.3371
SF295 CTRP2 7.8459 9.4697 5.5005 0.4124
SNU-466 CTRP2 7.8633 9.0627 5.6563 0.1276
SF126 CTRP2 7.8661 9.51 5.4937 0.4186
GMS-10 CTRP2 7.8952 8.9474 5.7075 0.0711
SNU-738 CTRP2 7.9205 9.297 5.5947 0.2038
GB-1 CTRP2 7.9452 10.1662 5.2695 0.9559
YKG-1 CTRP2 7.983 9.4384 5.5678 0.2302
SW1088 CTRP2 8.0218 9.8739 5.4207 0.5136
KG-1-C CTRP2 8.0228 9.3525 5.6135 0.1505
TM-31 CTRP2 8.0507 9.1191 5.7034 0.0557
YH-13 CTRP2 8.0733 9.4279 5.6057 0.1612
M059K CTRP2 8.0933 9.4912 5.5908 0.1783
NMC-G1 CTRP2 8.1031 9.3872 5.6308 0.1132
GaMG CTRP2 8.1079 9.4156 5.6227 0.1218
U-251MG CTRP2 8.1137 9.3181 5.6582 0.0828
A-172 CTRP2 8.1325 9.6256 5.5578 0.2048
Daoy CTRP2 8.1556 9.7186 5.5333 0.2376
SNU-201 CTRP2 8.1631 9.2817 5.6876 0.0525
U-118MG CTRP2 8.1658 10.4501 5.2583 0.8463
DBTRG-05MG CTRP2 8.2037 10.1615 5.3882 0.504
T98G CTRP2 8.3024 9.7315 5.5835 0.1326
ONS-76 CTRP2 8.3097 9.6942 5.599 0.1137
SF539 CTRP2 8.3432 9.7502 5.5918 0.1161
Becker CTRP2 8.3474 9.8824 5.5474 0.1691
8-MG-BA CTRP2 8.361 9.6724 5.6246 0.0872
D283 Med CTRP2 8.3932 9.5245 5.6848 0.0356
42-MG-BA CTRP2 8.439 9.8422 5.5943 0.0989
SNB-75 CTRP2 8.4708 10.2483 5.4638 0.262
LN-229 CTRP2 8.5024 10.2477 5.476 0.2344
SF268 CTRP2 8.5083 10.2187 5.4886 0.2144
GOS-3 CTRP2 8.538 10.0593 5.5551 0.1333
KALS-1 CTRP2 9.9096 18.8514 2.504 8.6053
KNS-60 CTRP2 11.0199 32.4086 -3.2563 22.643
KNS-81 CTRP2 11.9681 34.2544 -3.4807 21.8707
⏷ Show the Full List of 43 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 21 Cell Line(s) in Endometrium Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
MFE-319 CTRP2 7.2418 18.4244 0.8218 19.4083
HEC-265 CTRP2 7.3774 34.4814 -7.0791 33.2706
JHUEM-1 CTRP2 7.672 9.6432 5.3523 0.9023
HEC-1-B CTRP2 7.9549 9.4329 5.5588 0.2545
HEC-59 CTRP2 7.9685 9.763 5.4404 0.4929
EN CTRP2 8.1151 9.4961 5.5972 0.1525
HEC-6 CTRP2 8.1329 20.3785 0.5347 17.7391
RL95-2 CTRP2 8.171 9.6564 5.5614 0.1898
ESS-1 CTRP2 8.2272 9.5023 5.6354 0.0955
JHUEM-2 CTRP2 8.2381 9.9085 5.4965 0.2751
HEC-151 CTRP2 8.2547 9.9778 5.4777 0.303
HEC-108 CTRP2 8.3656 9.7561 5.5977 0.1063
EFE-184 CTRP2 8.3726 10.2225 5.4347 0.3425
AN3-CA CTRP2 8.5967 10.3453 5.4769 0.2103
HEC-1-A CTRP2 8.6119 10.2219 5.5256 0.1446
JHUEM-3 CTRP2 8.6298 10.5635 5.4114 0.3026
KLE CTRP2 8.6662 10.7152 5.3704 0.3627
HEC-50B CTRP2 9.0075 20.1345 1.29 13.9823
MFE-296 CTRP2 9.0388 10.7442 5.4982 0.108
HEC-251 CTRP2 11.0065 25.9152 -0.1219 15.4403
Ishikawa (Heraklio) 02 ER- CTRP2 7.2138 8.6397 5.5431 0.6602
⏷ Show the Full List of 21 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 20 Cell Line(s) in Kidney Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
TUHR10TKB CTRP2 6.9515 11.22 4.1681 6.2953
A-498 CTRP2 7.3591 9.11 5.4189 1.0021
RCC10RGB CTRP2 7.4631 9.4516 5.3273 1.142
TUHR4TKB CTRP2 7.7614 9.4858 5.4576 0.5558
OS-RC-2 CTRP2 7.7698 11.1365 4.7521 2.8671
BFTC-909 CTRP2 7.8647 9.1811 5.6149 0.1868
KMRC-3 CTRP2 7.8682 10.3027 5.1744 1.3015
VMRC-RCZ CTRP2 7.9383 9.8804 5.3813 0.7017
SNU-1272 CTRP2 7.9572 9.3708 5.5822 0.2137
769-P CTRP2 8.1136 10.3748 5.2644 0.8615
VMRC-RCW CTRP2 8.2801 9.9405 5.5012 0.2547
KMRC-2 CTRP2 8.3254 9.3237 5.728 0.0199
CAL-54 CTRP2 8.3472 9.9628 5.5189 0.2092
ACHN CTRP2 8.3504 15.7488 2.9535 9.0271
KMRC-1 CTRP2 8.3654 9.7776 5.5903 0.1141
Caki-2 CTRP2 8.3796 9.8945 5.5549 0.1641
KMRC-20 CTRP2 8.5106 10.0969 5.5322 0.1555
786-O CTRP2 8.7275 10.3814 5.5121 0.14
Caki-1 CTRP2 8.8384 10.6086 5.4735 0.177
TUHR14TKB CTRP2 9.2906 11.3377 5.3844 0.1875
⏷ Show the Full List of 20 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 40 Cell Line(s) in Large Intestine Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
HCC-56 CTRP2 6.8985 11.0811 4.1975 6.259
OUMS-23 CTRP2 7.2306 8.8485 5.4639 0.8932
LS180 CTRP2 7.3032 9.3664 5.2781 1.4542
COLO205 CTRP2 7.353 9.7738 5.1244 1.9535
KM12 CTRP2 7.4763 11.4722 4.4111 4.5423
DLD-1 CTRP2 7.4861 19.9741 0.2416 19.7082
HT-55 CTRP2 7.5131 8.865 5.5903 0.3603
NCI-H508 CTRP2 7.5226 10.1343 5.0604 2.0063
SW48 CTRP2 7.5525 9.1807 5.4838 0.6063
HCT 15 CTRP2 7.5526 9.4676 5.3663 0.9471
SNU-C4 CTRP2 7.6229 8.8781 5.6307 0.2328
HT-29 CTRP2 7.626 10.9774 4.7382 3.0835
HCT 8 CTRP2 7.7113 8.8992 5.6574 0.1613
CW-2 CTRP2 7.8042 9.7745 5.3619 0.7854
RCM-1 [Human ESC] CTRP2 7.9269 9.3116 5.5919 0.2066
HT115 CTRP2 7.9371 9.1798 5.6425 0.1304
MDST8 CTRP2 7.9618 9.2379 5.6312 0.14
SW948 CTRP2 7.9625 9.3211 5.6021 0.1811
SW620 CTRP2 7.9773 10.9224 4.9656 1.895
HCT 116 CTRP2 8.0002 12.643 4.1977 4.6949
LoVo CTRP2 8.0851 9.8197 5.4679 0.3824
SNU-407 CTRP2 8.1012 10.3221 5.2798 0.8273
LS1034 CTRP2 8.1107 9.6229 5.5505 0.2223
RKO CTRP2 8.1565 14.1268 3.5989 6.813
SNU-C5 CTRP2 8.203 11.7859 4.7104 2.5632
SW1417 CTRP2 8.2098 9.7309 5.5496 0.1977
LS411N CTRP2 8.2988 9.4697 5.6712 0.0513
LS123 CTRP2 8.3076 9.8122 5.5573 0.1644
NCI-H716 CTRP2 8.3306 9.93 5.5243 0.2053
SNU-C1 CTRP2 8.3528 16.7423 2.4757 10.8161
GP2d CTRP2 8.3529 9.8215 5.5706 0.1386
SK-CO-1 CTRP2 8.3981 10.2439 5.437 0.3298
LS513 CTRP2 8.4748 9.8822 5.5932 0.0949
SNU-1033 CTRP2 8.5936 10.7362 5.3334 0.4592
CL-11 CTRP2 8.6028 10.5277 5.4138 0.3065
T84 CTRP2 8.6159 10.5164 5.423 0.2875
NCI-H747 CTRP2 8.6182 10.7266 5.347 0.4231
SNU-61 CTRP2 8.7251 10.3056 5.5372 0.114
C2BBe1 CTRP2 8.9116 10.5739 5.5115 0.1126
SNU-C2A CTRP2 8.9725 16.7716 2.8808 8.4438
⏷ Show the Full List of 40 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 18 Cell Line(s) in Liver Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
JHH-6 CTRP2 7.0809 7.9086 5.7714 0.1668
HuH-1 CTRP2 7.4099 9.7074 5.1868 1.7939
Hep-G2 CTRP2 7.7978 9.1841 5.5878 0.2532
JHH-4 CTRP2 7.8293 10.3491 5.1345 1.4619
JHH-1 CTRP2 7.9424 9.1317 5.6612 0.1145
SNU-878 CTRP2 7.9905 9.7927 5.4385 0.4872
SNU-398 CTRP2 8.0111 10.4209 5.1965 1.1249
SK-HEP-1 CTRP2 8.0686 9.2374 5.6698 0.078
JHH-5 CTRP2 8.0766 10.2501 5.2973 0.7949
Hep 3B2.1-7 CTRP2 8.2961 9.4789 5.6672 0.0543
SNU-423 CTRP2 8.3188 9.8914 5.5335 0.1947
JHH-2 CTRP2 8.4271 10.0871 5.5048 0.226
HLF CTRP2 8.4338 9.8216 5.5995 0.1017
PLC/PRF/5 CTRP2 8.4799 9.8922 5.5916 0.1029
SNU-449 CTRP2 8.7675 10.5984 5.4511 0.2075
Li-7 CTRP2 8.8414 10.6716 5.4527 0.1899
SNU-182 CTRP2 9.1464 11.264 5.3573 0.2519
SNU-761 CTRP2 10.5505 35.27 -5.0041 26.2555
⏷ Show the Full List of 18 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 121 Cell Line(s) in Lung Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
NCI-H1184 CTRP2 5.3098 11.4272 2.7187 15.3551
LK2 CTRP2 6.6344 18.8704 0.1162 21.6155
NCI-H2087 CTRP2 6.8561 12.9078 3.2634 10.1547
MOR/CPR CTRP2 7.1143 11.4363 4.1797 5.9946
EPLC-272H CTRP2 7.142 9.6716 5.0436 2.5002
NCI-H196 CTRP2 7.2154 9.058 5.3653 1.2354
LOU-NH91 CTRP2 7.327 11.555 4.2709 5.3099
NCI-H446 CTRP2 7.33 10.085 4.9685 2.5603
RERF-LC-Ad1 CTRP2 7.3436 8.2548 5.748 0.1179
SBC-5 CTRP2 7.3468 9.865 5.0794 2.1254
NCI-H460 CTRP2 7.4025 9.6884 5.191 1.6624
Lu-99 CTRP2 7.4718 9.7158 5.2175 1.503
NCI-H2126 CTRP2 7.6519 9.4299 5.4298 0.6931
COR-L95 CTRP2 7.7026 9.3584 5.4814 0.5274
LC-1/sq-SF CTRP2 7.7775 8.9426 5.6669 0.1319
NCI-H358 CTRP2 7.7778 12.5708 4.0881 5.4107
LCLC-103H CTRP2 7.8015 9.1934 5.5858 0.2555
NCI-H1915 CTRP2 7.8139 9.287 5.5562 0.3081
KNS-62 CTRP2 7.8412 9.3397 5.5477 0.3147
NCI-H2171 CTRP2 7.844 9.1347 5.6237 0.1787
NCI-H1105 CTRP2 7.8667 9.7097 5.4165 0.6475
NCI-H1581 CTRP2 7.9087 9.5479 5.4972 0.3925
PC-14 CTRP2 7.9293 13.778 3.6133 7.0712
NCI-H2291 CTRP2 7.954 9.905 5.3787 0.6514
Sq-1 CTRP2 7.9761 9.641 5.4901 0.3798
HCC95 CTRP2 7.9771 9.6148 5.5004 0.3581
NCI-H650 CTRP2 7.9962 10.1484 5.3008 0.8342
NCI-H526 CTRP2 8.0016 9.2942 5.6262 0.1382
NCI-H69 CTRP2 8.0042 9.8202 5.4338 0.4915
HCC827 CTRP2 8.0166 9.4726 5.5684 0.2195
NCI-H2106 CTRP2 8.0221 9.7903 5.4528 0.4406
COLO 699 CTRP2 8.037 10.2397 5.2831 0.8577
NCI-H2009 CTRP2 8.0389 9.4477 5.5858 0.1863
NCI-H1563 CTRP2 8.0454 9.3963 5.6065 0.1551
HCC44 CTRP2 8.0553 10.1775 5.3165 0.756
NCI-H146 CTRP2 8.0626 9.6406 5.5253 0.2797
NCI-H1341 CTRP2 8.0675 9.4167 5.6075 0.1489
HCC4006 CTRP2 8.09 9.4448 5.6059 0.1462
NCI-H292 CTRP2 8.0963 10.5782 5.1732 1.1337
NCI-H841 CTRP2 8.1067 9.9723 5.4193 0.4778
NCI-H2081 CTRP2 8.1132 9.8156 5.481 0.3455
NCI-H1792 CTRP2 8.1195 9.7905 5.4928 0.3205
NCI-H2030 CTRP2 8.1255 10.3387 5.2844 0.8003
SK-LU-1 CTRP2 8.1278 10.6418 5.1622 1.1438
NCI-H2228 CTRP2 8.1299 17.7222 1.8391 13.4614
DMS 273 CTRP2 8.1492 9.9335 5.4517 0.4196
NCI-H2085 CTRP2 8.1516 10.3234 5.3023 0.7382
NCI-H1734 CTRP2 8.1525 10.1019 5.3892 0.525
HCC1438 CTRP2 8.1626 9.4616 5.6265 0.1079
NCI-H2023 CTRP2 8.1645 10.9998 5.0308 1.5201
NCI-H1155 CTRP2 8.1805 9.6821 5.5559 0.1956
NCI-H1793 CTRP2 8.1827 9.578 5.5934 0.1434
NCI-H2122 CTRP2 8.1994 10.1784 5.3798 0.5247
HCC15 CTRP2 8.2151 10.3178 5.3328 0.6278
IA-LM CTRP2 8.2419 9.7367 5.5595 0.1758
DMS 114 CTRP2 8.2439 10.0096 5.4618 0.3359
Calu-6 CTRP2 8.2518 10.3578 5.3333 0.6084
SW1573 CTRP2 8.2526 11.1045 5.0314 1.4492
NCI-H1755 CTRP2 8.2634 10.3628 5.3364 0.5953
NCI-H2405 CTRP2 8.2723 10.0995 5.4399 0.3677
SHP-77 CTRP2 8.2725 9.6169 5.6123 0.1055
RERF-LC-Ad2 CTRP2 8.2782 9.6325 5.609 0.1081
NCI-H838 CTRP2 8.2953 9.6504 5.6089 0.1055
NCI-H1975 CTRP2 8.3063 9.9727 5.4997 0.2497
NCI-H1339 CTRP2 8.3162 9.6323 5.6225 0.0955
HARA [Human squamous cell lung carcinoma] CTRP2 8.3352 12.0573 4.6642 2.5957
SK-MES-1 CTRP2 8.3368 9.914 5.5323 0.1923
HCC2279 CTRP2 8.3566 10.7852 5.2121 0.8571
NCI-H520 CTRP2 8.3614 10.035 5.4985 0.2367
NCI-H1838 CTRP2 8.3808 9.8577 5.5682 0.1364
Calu-3 CTRP2 8.3897 9.9288 5.5467 0.1612
NCI-H1373 CTRP2 8.404 11.3662 4.9976 1.4387
NCI-H1703 CTRP2 8.4109 9.9547 5.5454 0.1586
NCI-H322 CTRP2 8.4482 9.9668 5.5547 0.1504
HCC1171 CTRP2 8.4822 13.4791 4.1087 4.4536
NCI-H1944 CTRP2 8.4909 10.3042 5.4513 0.2766
VMRC-LCD CTRP2 8.4918 9.9706 5.5691 0.1166
SW1271 CTRP2 8.5193 22.1781 -0.0643 18.8629
NCI-H1395 CTRP2 8.5233 10.5348 5.3798 0.3937
RERF-LC-A1 CTRP2 8.5352 10.0536 5.5561 0.1236
EBC-1 CTRP2 8.5362 10.3837 5.4401 0.282
HCC78 CTRP2 8.5363 23.6112 -0.7586 20.6981
COR-L47 CTRP2 8.5538 11.904 4.8472 1.7913
NCI-H647 CTRP2 8.5592 10.3439 5.4632 0.2394
NCI-H23 CTRP2 8.5665 10.18 5.5236 0.1552
NCI-H211 CTRP2 8.5666 10.2573 5.4967 0.1897
RERF-LC-MS CTRP2 8.5796 10.2256 5.5126 0.1664
NCI-H1573 CTRP2 8.5825 10.1687 5.5333 0.1409
Calu-1 CTRP2 8.5903 9.9446 5.6123 0.0655
HCC366 CTRP2 8.622 10.4081 5.4641 0.2226
NCI-H1355 CTRP2 8.6353 11.8621 4.9057 1.5471
HCC1195 CTRP2 8.6758 14.012 3.9814 4.7046
NCI-H1568 CTRP2 8.6964 10.3686 5.5053 0.1532
A-549 CTRP2 8.7253 10.4766 5.4782 0.1807
NCI-H1651 CTRP2 8.7271 10.559 5.45 0.2181
DMS 454 CTRP2 8.7377 11.001 5.2934 0.4847
DMS 53 CTRP2 8.7418 10.5684 5.4521 0.2118
NCI-H2342 CTRP2 8.7439 10.5852 5.4469 0.2185
HCC2935 CTRP2 8.7622 10.3062 5.55 0.0969
ChaGo-K-1 CTRP2 8.7761 10.8359 5.3695 0.33
COR-L105 CTRP2 8.8121 10.6952 5.4335 0.2381
HCC2108 CTRP2 8.8583 15.2122 3.5395 6.1354
LCLC-97TM1 CTRP2 8.8671 10.7024 5.4513 0.1865
NCI-H1299 CTRP2 8.8675 10.9007 5.3814 0.285
NCI-H2444 CTRP2 8.935 37.7094 -7.4483 31.5666
NCI-H1869 CTRP2 8.9647 10.4603 5.5679 0.0617
NCI-H1650 CTRP2 8.971 11.1071 5.3469 0.3115
NCI-H2110 CTRP2 8.9914 10.7284 5.487 0.1251
NCI-H2170 CTRP2 9.014 10.681 5.511 0.0999
NCI-H226 CTRP2 9.1201 25.5836 -1.2954 21.1215
NCI-H1666 CTRP2 9.1287 12.0231 5.0694 0.806
NCI-H661 CTRP2 9.1978 18.583 2.1684 10.7145
HOP-92 CTRP2 9.2661 11.0558 5.472 0.103
LXF 289 CTRP2 9.323 15.9037 3.505 5.7154
EKVX CTRP2 9.3743 11.3968 5.3941 0.1625
BEN CTRP2 9.8836 39.3386 -7.5214 30.4505
HCC1833 CTRP2 9.9664 23.8619 0.1547 16.0732
CAL-12T CTRP2 10.2315 54.991 -15.033 36.1763
NCI-H1435 CTRP2 10.9033 23.8357 0.7991 12.9254
HCC1588 CTRP2 12.7712 51.6145 -11.4064 31.1364
Hs 888.Lu CTRP2 8.965 10.6089 5.5183 0.0995
⏷ Show the Full List of 121 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 2 Cell Line(s) in Thigh Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
H-STS CTRP2 7.2131 8.117 5.7474 0.1555
SYO-1 CTRP2 13.6 28.672 0.2351 11.4422
Cancer Drug Sensitivity Data Curated from 22 Cell Line(s) in Soft Tissue Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
Yamato-SS CTRP2 7.9791 9.4584 5.5589 0.2465
Aska-SS CTRP2 12.7613 28.2898 -0.1032 13.2613
Rh41 CTRP2 6.5288 8.3043 5.2883 2.3562
Tm87-16 CTRP2 7.1665 11.4061 4.2313 5.7055
RKN CTRP2 7.4051 10.1739 4.9733 2.4547
BT-12 CTRP2 7.4282 8.2728 5.7727 0.069
Rh18 CTRP2 7.4507 9.8332 5.1539 1.7458
TTC-709 CTRP2 7.7589 13.1266 3.8102 6.5347
MES-SA CTRP2 7.8025 9.0027 5.6549 0.1534
TE 441.T CTRP2 7.9583 9.3163 5.6022 0.1955
SW982 CTRP2 7.9933 20.4552 0.3917 18.4002
Hs 729.T CTRP2 8.0761 9.4777 5.5892 0.1723
BT-16 CTRP2 8.1614 9.4315 5.6363 0.0976
A-204 CTRP2 8.2416 11.5936 4.8162 2.1605
HT-1080 CTRP2 8.3243 9.6181 5.6302 0.0808
SK-UT-1 CTRP2 8.3686 10.0358 5.5009 0.2309
TE 617.T CTRP2 8.5523 10.0813 5.5527 0.1245
G-401 CTRP2 8.6074 10.4875 5.4302 0.2782
SK-LMS-1 CTRP2 8.6698 10.3418 5.505 0.1701
GCT CTRP2 8.6848 10.2935 5.527 0.1307
G-402 CTRP2 8.9567 11.2489 5.2898 0.4443
RD CTRP2 9.2909 10.8515 5.5484 0.0487
⏷ Show the Full List of 22 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 39 Cell Line(s) in Ovary Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
2004 CTRP2 11.369 28.937 -1.3259 18.0548
COV434 CTRP2 6.7647 8.8683 5.1782 2.4629
FU-OV-1 CTRP2 7.193 12.5409 3.6965 7.8396
OAW42 CTRP2 7.2464 8.4488 5.6355 0.4129
OV-90 CTRP2 7.341 18.4697 0.8765 18.023
TOV-21G CTRP2 7.4098 8.6351 5.6342 0.3309
OV56 CTRP2 7.4336 8.3641 5.7429 0.1119
OVISE CTRP2 7.4814 8.7234 5.6308 0.2852
JHOS-2 CTRP2 7.715 9.2049 5.5461 0.3691
OVK18 CTRP2 7.7204 9.1795 5.558 0.3412
ES2 CTRP2 7.7448 10.95 4.822 2.6367
OVSAHO CTRP2 7.7639 11.2398 4.7014 3.0624
TYK-nu CTRP2 7.7843 9.6122 5.4179 0.6455
SNU-8 CTRP2 7.8094 9.0166 5.6526 0.1444
Caov-3 CTRP2 7.8768 10.0949 5.2657 1.0144
DOV13 CTRP2 7.9423 9.9064 5.3729 0.673
JHOC-5 CTRP2 7.9577 10.2217 5.2527 0.9961
JHOM-1 CTRP2 7.9774 9.341 5.6006 0.1796
A2780 CTRP2 8.0076 10.8696 5.0047 1.7363
OC 314 CTRP2 8.0204 9.1328 5.6884 0.0674
SK-OV-3 CTRP2 8.0948 10.2109 5.3212 0.7212
RMG-I CTRP2 8.1175 10.4271 5.2451 0.9122
IGROV-1 CTRP2 8.2096 10.3979 5.299 0.7146
HEY A8 CTRP2 8.2568 9.6031 5.6114 0.1089
COV362 CTRP2 8.2979 9.6709 5.6028 0.1115
ONCO-DG-1 CTRP2 8.3072 9.7499 5.5789 0.1372
MCAS CTRP2 8.3519 10.1376 5.4577 0.3076
OAW28 CTRP2 8.3804 10.4819 5.3407 0.5313
OV7 CTRP2 8.4523 9.8734 5.5883 0.1105
TOV-112D CTRP2 8.4638 10.3087 5.4392 0.305
OVCAR-8 CTRP2 8.4779 11.4061 5.0174 1.3257
COV644 CTRP2 8.5026 10.0479 5.5463 0.14
EFO-21 CTRP2 8.5688 10.0442 5.5712 0.103
OVCAR-4 CTRP2 8.5777 10.4228 5.442 0.2674
EFO-27 CTRP2 8.7045 10.402 5.4966 0.162
SNU-119 CTRP2 8.7112 10.3535 5.5158 0.1386
OVTOKO CTRP2 8.8173 10.6869 5.4384 0.2138
Kuramochi CTRP2 8.8793 10.5046 5.5237 0.1056
SNU-840 CTRP2 10.2591 17.0336 3.5375 4.6233
⏷ Show the Full List of 39 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 7 Cell Line(s) in Pleura Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
IST-Mes1 CTRP2 7.8762 13.1485 3.8785 6.5456
ACC-MESO-1 CTRP2 8.0114 9.3144 5.6227 0.1407
NCI-H2052 CTRP2 8.1834 10.3766 5.2956 0.7376
MPP 89 CTRP2 8.2972 9.6981 5.5932 0.1223
JL-1 CTRP2 8.329 14.1258 3.7121 6.1462
NCI-H28 CTRP2 8.4109 10.2971 5.4225 0.3521
NCI-H2452 CTRP2 10.1928 23.4313 0.518 14.7017
⏷ Show the Full List of 7 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 5 Cell Line(s) in Prostate Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
22Rv1 CTRP2 7.8686 11.0684 4.8405 2.4385
VCaP CTRP2 7.913 9.3833 5.5604 0.2651
PaCa-3 CTRP2 8.094 9.423 5.615 0.1338
DU145 CTRP2 9.0328 10.5902 5.5479 0.0692
LNCaP clone FGC CTRP2 9.0708 10.8768 5.4644 0.1361
Cancer Drug Sensitivity Data Curated from 2 Cell Line(s) in Salivary Gland Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
YD-15 CTRP2 7.8022 9.1724 5.5938 0.2408
A-253 CTRP2 8.44 9.8568 5.5897 0.111
Cancer Drug Sensitivity Data Curated from 34 Cell Line(s) in Stomach Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
NCC-StC-K140 CTRP2 0.5637 4.8738 -3.5589 6.6481
GSU CTRP2 6.8503 7.8187 5.7048 0.4375
MKN1 CTRP2 7.1461 8.832 5.4263 1.0909
SH-10-TC CTRP2 7.2111 8.6054 5.556 0.624
MKN45 CTRP2 7.4809 8.5473 5.6956 0.1634
23132/87 CTRP2 7.5194 12.4304 3.9813 6.1951
ECC12 CTRP2 7.6315 8.6127 5.7285 0.0839
SNU-620 CTRP2 7.7376 8.8648 5.6794 0.1237
SNU-668 CTRP2 7.7634 8.9388 5.6629 0.1405
NCI-N87 CTRP2 7.7826 11.1533 4.752 2.8533
SNU-5 CTRP2 7.7966 9.1819 5.5881 0.253
GSS CTRP2 7.8035 9.0665 5.6326 0.1754
NUGC-4 CTRP2 7.8506 10.5041 5.079 1.6269
NUGC-3 CTRP2 8.0346 9.5956 5.5307 0.279
AGS CTRP2 8.0428 10.0737 5.352 0.6709
SNU-16 CTRP2 8.0804 9.1677 5.6974 0.0534
Fu97 CTRP2 8.1629 9.8354 5.4936 0.3043
HGC-27 CTRP2 8.2497 9.9378 5.4904 0.2822
SNU-216 CTRP2 8.291 10.0522 5.4649 0.3143
HuG1-N CTRP2 8.2963 10.0404 5.4713 0.3011
IM95 CTRP2 8.3316 10.3954 5.3531 0.5254
ECC10 CTRP2 8.3658 12.8808 4.3124 3.8299
LMSU CTRP2 8.5736 9.8694 5.6316 0.0536
Hs 746.T CTRP2 8.7243 10.019 5.6328 0.0444
SNU-1 CTRP2 8.7679 10.2624 5.5668 0.0819
SNU-601 CTRP2 8.8311 10.1261 5.6333 0.0346
MKN7 CTRP2 9.1054 10.7239 5.5281 0.0763
MKN74 CTRP2 9.4246 11.0795 5.5181 0.0561
KE-39 CTRP2 10.0148 12.0673 5.3903 0.0881
KATO III CTRP2 10.5118 28.0747 -1.5062 19.6189
SNU-719 CTRP2 11.1223 24.3493 0.6989 12.9492
SNU-1077 CTRP2 7.3584 9.3866 5.2996 1.3271
SNU-685 CTRP2 7.7752 8.9547 5.6617 0.1395
SNG-M CTRP2 7.8787 10.2469 5.2033 1.2026
⏷ Show the Full List of 34 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 12 Cell Line(s) in Thyroid Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
ML-1 [Human leukemia] CTRP2 6.1411 65.1871 -23.4464 43.0192
8305C CTRP2 7.5866 9.3118 5.4469 0.6866
B-CPAP CTRP2 7.7089 8.7934 5.6939 0.1109
SW579 CTRP2 7.8008 8.964 5.6679 0.1255
CAL-62 CTRP2 7.9115 9.1872 5.6304 0.1521
FTC-238 CTRP2 7.9403 9.2139 5.6317 0.1546
CGTH-W-1 CTRP2 7.9845 9.2815 5.6243 0.1443
BHT-101 CTRP2 8.1088 9.4745 5.6025 0.1468
8505C CTRP2 8.6022 10.815 5.3074 0.5094
FTC-133 CTRP2 8.6552 10.1526 5.5647 0.0974
TT2609-C02 CTRP2 8.8737 10.4135 5.5525 0.0877
TT CTRP2 10.6919 41.8126 -8.1296 30.163
⏷ Show the Full List of 12 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 29 Cell Line(s) in Upper Aerodigestive Tract Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
SCC-25 CTRP2 7.4393 10.5179 4.8357 2.9352
YD-10B CTRP2 7.4719 9.1912 5.4413 0.7797
CAL-27 CTRP2 7.5625 9.3666 5.413 0.859
FaDu CTRP2 7.6578 11.2033 4.6534 3.3677
PE/CA-PJ49 CTRP2 7.788 9.239 5.5635 0.3032
HSC-4 CTRP2 7.8171 9.6612 5.4133 0.6386
SNU-1076 CTRP2 7.8218 9.2314 5.5799 0.2596
SNU-899 CTRP2 7.8647 9.4887 5.5012 0.4027
Detroit 562 CTRP2 8.0178 9.6596 5.5003 0.3427
BICR 6 CTRP2 8.0489 9.1539 5.6911 0.0617
SNU-1066 CTRP2 8.0611 9.4573 5.5908 0.1736
PE/CA-PJ41 (clone D2) CTRP2 8.1064 9.4829 5.5986 0.1524
HSC-3 CTRP2 8.1113 9.4165 5.6236 0.1201
SNU-46 CTRP2 8.1243 9.8662 5.4666 0.3699
HSC-2 CTRP2 8.1822 9.5755 5.594 0.1533
BICR 18 CTRP2 8.2343 9.8319 5.5227 0.2327
BICR 56 CTRP2 8.3296 9.6096 5.6349 0.076
PE/CA-PJ15 CTRP2 8.3899 9.8928 5.5593 0.1454
BHY CTRP2 8.4143 10.1279 5.4854 0.2431
SNU-1041 CTRP2 8.4361 9.9328 5.5622 0.1335
BICR 16 CTRP2 8.4455 9.866 5.5884 0.1038
SCC-9 CTRP2 8.4676 10.1065 5.513 0.2033
BICR 22 CTRP2 8.4728 10.0469 5.5358 0.1583
SNU-1214 CTRP2 8.5006 10.3946 5.4223 0.3231
SCC-4 CTRP2 8.5014 10.0605 5.5415 0.1459
CAL-33 CTRP2 8.5153 10.1158 5.5273 0.1606
BICR 31 CTRP2 8.6558 10.1834 5.5544 0.107
PE/CA-PJ34 (clone C12) CTRP2 8.891 10.4694 5.5397 0.0901
YD-8 CTRP2 11.1285 22.0313 1.7859 9.568
⏷ Show the Full List of 29 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 22 Cell Line(s) in Urinary Tract Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
253J CTRP2 7.4707 8.8955 5.5599 0.4543
639V CTRP2 7.4986 8.5139 5.7143 0.1296
BC-3C CTRP2 7.6003 9.2631 5.4729 0.652
BFTC-905 CTRP2 7.696 9.1854 5.5455 0.3786
5637 CTRP2 7.7941 10.8894 4.8779 2.3811
TCCSUP CTRP2 7.8098 10.6679 4.9853 1.9848
647V CTRP2 7.8188 9.3885 5.52 0.4096
VM-CUB-1 CTRP2 7.9083 10.3285 5.1839 1.2401
RT-112 CTRP2 8.0918 9.5128 5.5826 0.178
CAL-29 CTRP2 8.11 9.4039 5.6275 0.1158
253J-BV CTRP2 8.1191 9.4631 5.6102 0.1348
JMSU-1 CTRP2 8.1319 9.3332 5.6595 0.0791
HT-1197 CTRP2 8.1736 9.4891 5.6209 0.1122
SCaBER CTRP2 8.2073 9.546 5.6134 0.1235
J82 CTRP2 8.3231 10.3374 5.3716 0.4885
UM-UC-3 CTRP2 8.3477 12.5159 4.4668 3.2849
RT-4 CTRP2 8.3582 12.9305 4.2851 3.9391
T24 CTRP2 8.552 10.2707 5.4865 0.2224
HT-1376 CTRP2 8.5619 10.3646 5.4569 0.2484
UM-UC-1 CTRP2 8.7666 10.1238 5.6125 0.0499
KMBC-2 CTRP2 8.8551 10.4233 5.5428 0.0918
KU-19-19 CTRP2 12.3584 32.9322 -2.5708 19.5971
⏷ Show the Full List of 22 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 1 Cell Line(s) in Urogenital System Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
HeLa CTRP2 7.4577 8.8644 5.5664 0.445

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Disease Different from Procarbazine (Comorbidity)
DDI Drug Name DDI Drug ID Severity Mechanism Comorbidity REF
Mepyramine DMB4SFH Moderate Additive CNS depression effects by the combination of Procarbazine and Mepyramine. Allergic/hypersensitivity disorder [4A80-4A8Z] [7]
Phenyltoloxamine DMKAEQW Moderate Additive CNS depression effects by the combination of Procarbazine and Phenyltoloxamine. Allergic/hypersensitivity disorder [4A80-4A8Z] [7]
Amyl nitrite DMJKO05 Moderate Additive hypotensive effects by the combination of Procarbazine and Amyl nitrite. Angina pectoris [BA40] [8]
Levalbuterol DM5YBO1 Moderate Additive hypertensive effects by the combination of Procarbazine and Levalbuterol. Asthma [CA23] [9]
Pirbuterol DMI5678 Moderate Additive hypertensive effects by the combination of Procarbazine and Pirbuterol. Asthma [CA23] [10]
Ephedrine DMMV0KW Major Additive hypertensive effects by the combination of Procarbazine and Ephedrine. Asthma [CA23] [8]
Roflumilast DMPGHY8 Moderate Additive immunosuppressive effects by the combination of Procarbazine and Roflumilast. Asthma [CA23] [11]
Lisdexamfetamine DM6W8V5 Major Increased risk of hyperpyrexia by the combination of Procarbazine and Lisdexamfetamine. Attention deficit hyperactivity disorder [6A05] [8]
Droxidopa DM5YF4M Moderate Additive hypertensive effects by the combination of Procarbazine and Droxidopa. Autonomic nervous system disorder [8D87] [12]
Sparfloxacin DMB4HCT Minor Decreased absorption of Procarbazine due to intestinal mucosa variation caused by Sparfloxacin. Bacterial infection [1A00-1C4Z] [13]
ABT-492 DMJFD2I Minor Decreased absorption of Procarbazine due to intestinal mucosa variation caused by ABT-492. Bacterial infection [1A00-1C4Z] [13]
Olodaterol DM62B78 Moderate Additive hypertensive effects by the combination of Procarbazine and Olodaterol. Chronic obstructive pulmonary disease [CA22] [10]
Vilanterol DMF5EK1 Moderate Additive hypertensive effects by the combination of Procarbazine and Vilanterol. Chronic obstructive pulmonary disease [CA22] [9]
Indacaterol DMQJHR7 Moderate Additive hypertensive effects by the combination of Procarbazine and Indacaterol. Chronic obstructive pulmonary disease [CA22] [10]
Arformoterol DMYM974 Moderate Additive hypertensive effects by the combination of Procarbazine and Arformoterol. Chronic obstructive pulmonary disease [CA22] [10]
Levomilnacipran DMV26S8 Major Additive serotonergic effects by the combination of Procarbazine and Levomilnacipran. Chronic pain [MG30] [14]
Cyclandelate DMO0R76 Moderate Additive hypotensive effects by the combination of Procarbazine and Cyclandelate. Dementia [6D80-6D8Z] [8]
Isocarboxazid DMAF1NB Major Additive hypertensive effects by the combination of Procarbazine and Isocarboxazid. Depression [6A70-6A7Z] [15]
Milnacipran DMBFE74 Major Additive serotonergic effects by the combination of Procarbazine and Milnacipran. Depression [6A70-6A7Z] [14]
Escitalopram DMFK9HG Major Additive serotonergic effects by the combination of Procarbazine and Escitalopram. Depression [6A70-6A7Z] [16]
Desvenlafaxine DMHD4PE Major Additive serotonergic effects by the combination of Procarbazine and Desvenlafaxine. Depression [6A70-6A7Z] [14]
Clomipramine DMINRKW Major Additive serotonergic effects by the combination of Procarbazine and Clomipramine. Depression [6A70-6A7Z] [17]
5-hydroxy-L-tryptophan DMDWZGJ Major Additive serotonergic effects by the combination of Procarbazine and 5-hydroxy-L-tryptophan. Discovery agent [N.A.] [18]
LEVONORDEFRIN DMWDJ0H Moderate Additive hypertensive effects by the combination of Procarbazine and LEVONORDEFRIN. Discovery agent [N.A.] [19]
Tetrabenazine DMYWQ0O Major Additive hypertensive effects by the combination of Procarbazine and Tetrabenazine. Dissociative neurological symptom disorder [6B60] [20]
Deutetrabenazine DMUPFLI Major Additive hypertensive effects by the combination of Procarbazine and Deutetrabenazine. Dystonic disorder [8A02] [20]
Guanethidine DM9NSWT Moderate Antagonize the effect of Procarbazine when combined with Guanethidine. Essential hypertension [BA00] [21]
Mephentermine DMFJH5Q Major Additive hypertensive effects by the combination of Procarbazine and Mephentermine. Essential hypertension [BA00] [8]
Nesiritide DMFOIA8 Moderate Additive hypotensive effects by the combination of Procarbazine and Nesiritide. Heart failure [BD10-BD1Z] [8]
Tetrahydrozoline DMT57WC Moderate Decreased metabolism of Procarbazine caused by Tetrahydrozoline mediated inhibition of non-CYP450 enzyme. Herpes simplex infection [1F00] [22]
Maraviroc DMTL94F Moderate Additive hypotensive effects by the combination of Procarbazine and Maraviroc. Human immunodeficiency virus disease [1C60-1C62] [8]
Teriflunomide DMQ2FKJ Major Additive immunosuppressive effects by the combination of Procarbazine and Teriflunomide. Hyper-lipoproteinaemia [5C80] [23]
Aliskiren DM1BV7W Moderate Additive hypotensive effects by the combination of Procarbazine and Aliskiren. Hypertension [BA00-BA04] [8]
Captopril DM458UM Moderate Additive hypotensive effects by the combination of Procarbazine and Captopril. Hypertension [BA00-BA04] [8]
Levamlodipine DM92S6N Moderate Additive hypotensive effects by the combination of Procarbazine and Levamlodipine. Hypertension [BA00-BA04] [8]
TAK-491 DMCF6SX Moderate Additive hypotensive effects by the combination of Procarbazine and TAK-491. Hypertension [BA00-BA04] [8]
Clevidipine butyrate DMW4M97 Moderate Additive hypotensive effects by the combination of Procarbazine and Clevidipine butyrate. Hypertension [BA00-BA04] [8]
Naphazoline DMJFZDL Moderate Decreased metabolism of Procarbazine caused by Naphazoline mediated inhibition of non-CYP450 enzyme. Itching [1F28-1G07] [22]
Denosumab DMNI0KO Moderate Additive myelosuppressive effects by the combination of Procarbazine and Denosumab. Low bone mass disorder [FB83] [24]
Allopregnanolone DMNLHAC Moderate Additive CNS depression effects by the combination of Procarbazine and Allopregnanolone. Mental/behavioural/neurodevelopmental disorder [6E20-6E8Z] [25]
Lasmiditan DMXLVDT Major Additive serotonergic effects by the combination of Procarbazine and Lasmiditan. Migraine [8A80] [14]
Tecfidera DM2OVDT Moderate Additive immunosuppressive effects by the combination of Procarbazine and Tecfidera. Multiple sclerosis [8A40] [26]
Siponimod DM2R86O Major Additive immunosuppressive effects by the combination of Procarbazine and Siponimod. Multiple sclerosis [8A40] [27]
Fingolimod DM5JVAN Major Additive immunosuppressive effects by the combination of Procarbazine and Fingolimod. Multiple sclerosis [8A40] [28]
Ocrelizumab DMEZ2KH Moderate Additive immunosuppressive effects by the combination of Procarbazine and Ocrelizumab. Multiple sclerosis [8A40] [29]
Ozanimod DMT6AM2 Major Decreased metabolism of Procarbazine caused by Ozanimod mediated inhibition of non-CYP450 enzyme. Multiple sclerosis [8A40] [30]
Omacetaxine mepesuccinate DMPU2WX Moderate Additive immunosuppressive effects by the combination of Procarbazine and Omacetaxine mepesuccinate. Myeloproliferative neoplasm [2A20] [31]
Dextroamphetamine DMMIHVP Major Increased risk of hyperpyrexia by the combination of Procarbazine and Dextroamphetamine. Narcolepsy [7A20] [8]
Phenindamine DMDTC7R Moderate Additive CNS depression effects by the combination of Procarbazine and Phenindamine. Nasopharyngitis [CA00] [7]
Cyclizine DM9G7BS Moderate Additive CNS depression effects by the combination of Procarbazine and Cyclizine. Nausea/vomiting [MD90] [7]
Metoclopramide DMFA5MY Moderate Additive hypertensive effects by the combination of Procarbazine and Metoclopramide. Nausea/vomiting [MD90] [32]
Phendimetrazine DM6TS1N Major Increased risk of hyperpyrexia by the combination of Procarbazine and Phendimetrazine. Obesity [5B80-5B81] [8]
Lorcaserin DMG6OYJ Major Additive serotonergic effects by the combination of Procarbazine and Lorcaserin. Obesity [5B80-5B81] [33]
Dexfenfluramine DMJ7YDS Major Additive serotonergic effects by the combination of Procarbazine and Dexfenfluramine. Obesity [5B80-5B81] [14]
Propylhexedrine DMTBW2O Moderate Decreased metabolism of Procarbazine caused by Propylhexedrine mediated inhibition of non-CYP450 enzyme. Obesity [5B80-5B81] [22]
Polythiazide DMCH80F Moderate Additive hypotensive effects by the combination of Procarbazine and Polythiazide. Oedema [MG29] [8]
Lofexidine DM1WXA6 Moderate Additive hypotensive effects by the combination of Procarbazine and Lofexidine. Opioid use disorder [6C43] [8]
Methamphetamine DMPM4SK Major Increased risk of hyperpyrexia by the combination of Procarbazine and Methamphetamine. Pain [MG30-MG3Z] [34]
Levodopa DMN3E57 Major Additive hypertensive effects by the combination of Procarbazine and Levodopa. Parkinsonism [8A00] [8]
Silodosin DMJSBT6 Moderate Additive hypotensive effects by the combination of Procarbazine and Silodosin. Prostate hyperplasia [GA90] [8]
Levomepromazine DMIKFEL Moderate Additive hypotensive effects by the combination of Procarbazine and Levomepromazine. Psychotic disorder [6A20-6A25] [8]
Selexipag DMAHSU0 Moderate Additive hypotensive effects by the combination of Procarbazine and Selexipag. Pulmonary hypertension [BB01] [8]
Epoprostenol DMUTYR2 Moderate Additive hypotensive effects by the combination of Procarbazine and Epoprostenol. Pulmonary hypertension [BB01] [8]
Canakinumab DM8HLO5 Moderate Additive immunosuppressive effects by the combination of Procarbazine and Canakinumab. Rheumatoid arthritis [FA20] [35]
Rilonacept DMGLUQS Moderate Additive immunosuppressive effects by the combination of Procarbazine and Rilonacept. Rheumatoid arthritis [FA20] [35]
Golimumab DMHZV7X Major Additive immunosuppressive effects by the combination of Procarbazine and Golimumab. Rheumatoid arthritis [FA20] [36]
Anthrax vaccine DM9GSWY Moderate Antagonize the effect of Procarbazine when combined with Anthrax vaccine. Sepsis [1G40-1G41] [37]
Avanafil DM75CXN Moderate Additive hypotensive effects by the combination of Procarbazine and Avanafil. Sexual dysfunction [HA00-HA01] [8]
Trimeprazine DMEMV9D Moderate Additive hypotensive effects by the combination of Procarbazine and Trimeprazine. Vasomotor/allergic rhinitis [CA08] [19]
Xylometazoline DMKV32D Moderate Decreased metabolism of Procarbazine caused by Xylometazoline mediated inhibition of non-CYP450 enzyme. Vasomotor/allergic rhinitis [CA08] [22]
Acrivastine DMTIGA0 Moderate Additive CNS depression effects by the combination of Procarbazine and Acrivastine. Vasomotor/allergic rhinitis [CA08] [7]
Valganciclovir DMS2IUH Moderate Additive myelosuppressive effects by the combination of Procarbazine and Valganciclovir. Virus infection [1A24-1D9Z] [27]
⏷ Show the Full List of 72 DDI Information of This Drug

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG
DIG Name DIG ID PubChem CID Functional Classification
Mannitol E00103 6251 Diluent; Flavoring agent; Lyophilization aid; Plasticizing agent; Tonicity agent
methylparaben E00149 7456 Antimicrobial preservative
Propyl 4-hydroxybenzoate E00141 7175 Antimicrobial preservative
Quinoline yellow WS E00309 24671 Colorant
Sunset yellow FCF E00255 17730 Colorant
Gelatin E00630 Not Available Other agent
Potassium sorbate E00566 23676745 Antimicrobial preservative
Talc E00520 16211421 Anticaking agent; Diluent; Glidant; lubricant
Titanium dioxide E00322 26042 Coating agent; Colorant; Opacifying agent
⏷ Show the Full List of 9 Pharmaceutical Excipients of This Drug
Pharmaceutical Formulation
Formulation Name Drug Dosage Dosage Form Route
Procarbazine 50 mg capsule 50 mg Oral Capsule Oral
Procarbazine Hydrochloride 50mg capsule 50mg Capsule Oral
Jump to Detail Pharmaceutical Formulation Page of This Drug

References

1 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7278).
2 Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
3 Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose
4 Brca2/Xrcc2 dependent HR, but not NHEJ, is required for protection against O(6)-methylguanine triggered apoptosis, DSBs and chromosomal aberrations... DNA Repair (Amst). 2009 Jan 1;8(1):72-86.
5 In vitro and in vivo evidence for the formation of methyl radical from procarbazine: a spin-trapping study. Carcinogenesis. 1992 May;13(5):799-805.
6 Tumour cytochrome P450 and drug activation. Curr Pharm Des. 2002;8(15):1335-47.
7 Canadian Pharmacists Association.
8 Ban TA "Drug interactions with psychoactive drugs." Dis Nerv Syst 36 (1975): 164-6. [PMID: 1116424]
9 Boakes AJ, Laurence DR, Teoh PC, Barar FS, Benedikter LT, Prichard BN "Interactions between sympathomimetic amines and antidepressant agents in man." Br Med J 1 (1973): 311-5. [PMID: 4685619]
10 Adverse effects and complications of treatment with beta-adrenergic agonist drugs. Committee on drugs, the American Academy of Allergy and Immunology. J Allergy Clin Immunol 75 (1985): 443-9. [PMID: 2858503]
11 Cerner Multum, Inc. "UK Summary of Product Characteristics.".
12 Product Information. Northera (droxidopa). Chelsea Therapeutics Inc, Charlotte, NC.
13 Johnson EJ, MacGowan AP, Potter MN, et al "Reduced absorption of oral ciprofloxacin after chemotherapy for haematological malignancy." J Antimicrob Chemother 25 (1990): 837-42. [PMID: 2373666]
14 Alvine G, Black DW, Tsuang D "Case of delirium secondary to phenelzine/L-tryptophan combination." J Clin Psychiatry 51 (1990): 311. [PMID: 2365671]
15 Bazire SR "Sudden death associated with switching monoamine oxidase inhibitors." Drug Intell Clin Pharm 20 (1986): 954-6. [PMID: 3816543]
16 Beasley CM Jr, Masica DN, Heiligenstein JH, Wheadon DE, Zerbe RL "Possible monoamine oxidase inhibitor-serotonin uptake inhibitor interaction: fluoxetine clinical data and preclinical findings." J Clin Psychopharmacol 13 (1993): 312-20. [PMID: 8227489]
17 Boyer EW, Shannon M "The serotonin syndrome." N Engl J Med 352 (2005): 1112-20. [PMID: 15784664]
18 Graber MA, Hoehns TB, Perry PJ "Sertraline-phenelzine drug interaction: a serotonin syndrome reaction." Ann Pharmacother 28 (1994): 732-5. [PMID: 7919561]
19 Goldberg LI "Monoamine oxidase inhibitors: adverse reactions and possible mechanisms." JAMA 190 (1964): 456-62. [PMID: 14197995]
20 Product Information. Austedo (deutetrabenazine). Teva Pharmaceuticals USA, North Wales, PA.
21 Darcy PF, Griffin JP "Interactions with drugs used in the treatment of depressive illness." Adverse Drug React Toxicol Rev 14 (1995): 211-31. [PMID: 8845455]
22 Cusson JR, Goldenberg E, Larochelle P "Effect of a novel monoamine-oxidase inhibitor, moclobemide on the sensitivity to intravenous tyramine and norepinephrine in humans." J Clin Pharmacol 31 (1991): 462-7. [PMID: 2050833]
23 Product Information. Arava (leflunomide). Hoechst Marion-Roussel Inc, Kansas City, MO.
24 Product Information. Prolia (denosumab). Amgen USA, Thousand Oaks, CA.
25 Product Information. Zulresso (brexanolone). Sage Therapeutics, Inc., Cambridge, MA.
26 Product Information. Vumerity (diroximel fumarate). Alkermes, Inc, Cambridge, MA.
27 Cerner Multum, Inc. "Australian Product Information.".
28 Product Information. Gilenya (fingolimod). Novartis Pharmaceuticals, East Hanover, NJ.
29 Product Information. Ocrevus (ocrelizumab). Genentech, South San Francisco, CA.
30 Product Information. Zeposia (ozanimod). Celgene Corporation, Summit, NJ.
31 Product Information. Synribo (omacetaxine). Teva Pharmaceuticals USA, North Wales, PA.
32 Filibeck DJ, Grimm D, Forman WB, Leidner BA "Metoclopramide-induced hypertensive crisis." Clin Pharm 3 (1984): 548-9. [PMID: 6541544]
33 Product Information. Belviq (lorcaserin). Eisai Inc, Teaneck, NJ.
34 Boakes AJ, Laurence DR, Teoh PC, Barar FS, Benedikter LT, Pritchard BN "Interactions between sympathomimetic amines and antidepressant agents in man." Br Med J 1 (1973): 311-5. [PMID: 4685619]
35 Product Information. Arcalyst (rilonacept). Regeneron Pharmaceuticals Inc, Tarrytown, NY.
36 Product Information. Cimzia (certolizumab). UCB Pharma Inc, Smyrna, GA.
37 CDC. Centers for Disease Control and Prevention/ "Recommendations of the advisory committtee on immunization practices (ACIP): use of vaccines and immune globulins in persons with altered immunocompetence." MMWR Morb Mortal Wkly Rep 42(RR-04) (1993): 1-18. [PMID: 20300058]